🇺🇸

Index Intelligence

· daily

S&P 500 Healthcare Sector SEC Filings — March 12, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (including cross-sector context from financials and industrials), overarching themes reveal mixed financial performance with robust revenue/asset growth in 12/50 companies (avg +25% YoY where reported, e.g., Orrstown +25.7%, Acacia +133%) offset by margin compression in 8/50 (avg -150bps, e.g., Lennar gross margin 15.2% vs 18.7%) and widening losses in biotechs/financials (e.g., MBX +40% YoY loss). Healthcare-specific highlights include positive clinical catalysts (Solid Biosciences robust Phase 1/2 data, Precision Bio Q4 rev +5600% YoY to $34.2M) amid risks like Stryker's cyber disruption and Cassava's FDA hold. Capital allocation leans defensive with debt retirements (B. Riley $37.9M), repurchases (Lennar $237M, CION $5.2M), and stable dividends (CION $0.36/share), while M&A activity signals consolidation (Esquire-Signature merger at 2.63x exchange). Forward-looking data flags 15+ catalysts into H2 2026, including trial readouts and guidances, positioning selective biotechs for alpha despite sector net losses (9/12 healthcare filers). Portfolio-level trends show improving ROE in outperformers (Velocity +310bps to 17.5%) but rising provisions/NPLs in laggards, urging focus on clinical momentum over broad financials.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 11, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (with broader cross-sector context), sentiment is predominantly mixed (24/50 filings), reflecting resilient revenue growth in staples outliers like Costco (+9.3% YoY Q2 revenue to $69.6B) amid declines in core players like Campbell's (-5% YoY Q2 net sales to $2.6B, lowered FY2026 guidance). Portfolio-level trends show 12/28 quantifiable revenue reporters with YoY growth averaging +24% (e.g., Oracle +22%, Marvell +42%), but 10 with declines averaging -12% (e.g., Nuwellis -5.4%, Campbell's -4.5% six-month); margins compressed in 8/15 (avg -150bps, e.g., Travelzoo 80.3% vs 87.5%), offset by expansions in 5 (e.g., Marvell +970bps to 51%). Capital allocation leans shareholder-friendly with dividends (ICL $232M, 3.1% yield; Pangaea $0.05/share) and buybacks (Campbell's $172M remaining; Core Molding +$6.5M to $7.5M total), while M&A/divestitures active (Elutia $88M BioEnvelope sale; Katapult pending merger). Forward-looking data flags lowered guidance (Campbell's organic sales -2% to flat) but optimistic catalysts (Netskope FY2027 revenue $870-876M; Elutia FDA 2H26). Proxy-heavy filings (12/50) signal governance focus ahead of April AGMs, with no major insider selling patterns but positive buyback conviction. Implications: Staples face volume headwinds/storm impacts, favor growth outliers like Costco; monitor margin trends and Q1 2026 catalysts for portfolio rotation.

26 high priority 24 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 11, 2026

Across 50 SEC filings from S&P 500 Industrials and related entities dated March 11, 2026, the sector exhibits mixed FY2025 performance with 14/24 reporting companies showing revenue growth averaging +28% YoY (e.g., Serve Robotics +46%, Guardian Pharmacy +18%), but EBITDA declines in 7/15 cases averaging -35% (e.g., Target Hospitality -73%, Kewaunee flat amid backlog -17%). SPAC activity is volatile with 3 terminations/advances (Yotta negative, FG Merger II positive, GalaxyEdge IPO $100M), while M&A catalysts proliferate (Baker Hughes $9.5B notes for Chart, UWM pursuing Two Harbors). Guidance is constructive in 6 firms (Serve $26M 2026 rev up from prior, Guardian $120-124M EBITDA), but impairments and losses dominate (TechTarget $931M goodwill hit). Capital allocation leans defensive with dividends maintained (Heritage $0.13, UWM $0.10 quarterly), buybacks (Alpha Pro 685k shares), and low debt (Target Hosp zero net debt). Portfolio trends signal transportation/machinery resilience (Ryder EPS +8.4% YoY, TSR 146%) vs. construction/services weakness, with upcoming proxies/earnings as key catalysts.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 11, 2026

Across the 8 S&P 500 Energy stream filings (with contextual financials), dominant themes include accelerating M&A momentum in energy services and E&P (Baker Hughes' $6.5B+€3B notes for Chart acquisition closing March 11, 2026; Devon's Coterra merger org structure), offset by geopolitical disruptions at SLB impacting Q1 EPS by $0.06-0.09. Period-over-period trends show robust growth at Peapack Gladstone (net income +13.1% YoY to $37.3M, NII +34.8% to $200.9M, loans +13.4% to $6.25B), but rising provisions (+213% to $23.5M) and capital ratio decline (-2.16 pts to 12.68%). Proxy season ramps up with neutral sentiment for IBKR, SHW annual meetings in April 2026, featuring director elections and comp votes. Positive sentiments dominate M&A filings (BKR, DVN at 9/10 and 8/10 materiality), while SLB and PGC are mixed due to ops headwinds and expense pressures. Portfolio-level patterns signal consolidation opportunities amid geo risks, with no insider trading noted but strong capital raises indicating conviction. Implications: Bullish for M&A plays, cautious on international exposure; watch deal closures and Q1 guidance.

5 high priority 3 medium 8 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 11, 2026

Across 50 filings from S&P 500 Financials and adjacent sectors on March 11, 2026, dominant themes include heavy SPAC activity (12+ filings: IPOs, mergers, terminations, low redemptions), robust M&A (Cintas-UniFirst $5.5B, Contango-Dolly Varden), and mixed financial results with revenue growth outliers (AeroVironment +143% YoY Q3, TSS +66% FY, Acacia +133% FY) offset by declines (C3.ai -46% YoY Q3, Target Hospitality -17% FY). Period-over-period trends show average revenue growth ~20% YoY in high-performers but margin compression in 8/15 reporting companies (avg -150bps, e.g., Pangaea flat EBITDA margin, Smith Douglas -440bps gross margin), alongside capex surges (Oracle +$39.2B nine-months) and buyback/dividend commitments (News Corp $1B, ICL 3.1% yield). Capital allocation leans shareholder-friendly with buybacks/repurchases in 6 firms and dividends in 4, but SPAC redemptions average 6-92% signal dilution risks. Forward-looking data flags guidance cuts (Campbell's organic sales -2% to flat FY2026) and raises (TSS EBITDA $20-22M 2026), with catalysts like Contango special meeting March 17 and Cintas earnings March 25. Portfolio-level, financial services/SPACs show merger momentum but termination risks (Yotta), implying tactical opportunities in low-redemption de-SPACs (TLGY 6.7%) vs. avoid high-dilution IPOs (Pono 30% founder ownership). Overall, bullish M&A/deal flow contrasts deteriorating margins in growth names, favoring selective longs on guidance-backed outperformers.

25 high priority 25 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 11, 2026

Across 15 SEC filings from the S&P 500 Technology stream (including software, semiconductors, IT services), dominant themes include robust revenue growth in cloud segments (Oracle Q3 +22% YoY to $17.2B, Cloud +44% to $8.9B), positive shareholder approvals at multiple AGMs (Maximus 93.2% quorum, Comtech all proposals passed), and proactive capital allocation via buybacks (Palo Alto +$1B authorization) and dividend hikes (Smurfit Westrock +5% to $0.4523/share, Oracle nine-mo $1.50 vs $1.20). Period-over-period trends show net income surges (Community West +398% YoY to $38.2M, Oracle nine-mo +42% to $12.8B) but offset by rising capex/debt (Oracle $39.2B capex, $134.6B debt) and compliance risks (GameSquare 2nd Nasdaq extension to Sep 7, 2026). Portfolio-level patterns reveal 4/4 detailed financials with YoY revenue/NI growth averaging +100%+, mixed sentiment (6/15 mixed/neutral), and clustered AGMs in April-May 2026 as catalysts. Critical implications: Tech growth intact but capex-heavy; monitor delisting risks and proxy votes for governance signals. Overall, bullish on capital returns amid growth, cautious on leverage/compliance outliers.

9 high priority 6 medium 15 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 11, 2026

Across 12 NASDAQ-100 related SEC filings from March 11, 2026, dominant themes include strong 2025 financial performance in packaging and retail (Smurfit Westrock $31.2B sales + synergies exceeded, Costco Q2 revenue +9.3% YoY to $69.6B, net income +13.8%), positive shareholder approvals at AGMs (Maximus 93.2% quorum, Comtech all proposals passed), and proactive capital management via dividend hikes (Smurfit +5% to $0.4523/share) and debt refinancings (Warner Music $1.295B term loan). Banking names show recovery with Community West net income +398% YoY to $38.2M and First Community strong KPI attainment (core ROAA 1.60% vs 1.11% target), but mixed with rising nonaccruals and declining investment yields. Period-over-period trends highlight revenue/earnings growth averaging +10-15% YoY in outperformers like Costco vs sector pressures, with no insider selling noted but limited activity reported. Portfolio-level implications favor consumer staples/retail momentum, while proxy battles and adjourned meetings signal governance watchpoints. Forward catalysts cluster around May AGMs and April reorganizations, positioning for post-vote repricings.

8 high priority 4 medium 12 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 11, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (though spanning broader US blue-chips and growth names), overarching themes include robust revenue acceleration in tech/hardware (e.g., AeroVironment +143% YoY Q3, Marvell +42% FY2026) offset by widening net losses from impairments/acquisitions (9/15 quantified firms showed losses expanding >100% YoY). Proxy statements dominate (20+ filings) signaling Q2 AGM season with strong board approvals and capital returns (PNC $3.9B to shareholders). M&A activity shines (Sonida $1.8B merger +62% FFO accretion, UWM pursuing Two Harbors), while biotech/healthcare mixed on trials/cuts (Vistagen 20% workforce reduction). Capital allocation tilts to buybacks/dividends (Levi $363M returned +26% YoY, Life Time $500M repurchase), but delisting risks (GameSquare) and going concern doubts (Evofem) flag vulnerabilities. Portfolio-level: Revenue grew avg +30% YoY in 12/20 trendable firms, margins mixed (5 expanded >500bps, 7 compressed), with positive FCF emerging (Netskope +$12.4M FY). Critical implications: Favor growth acquirers amid volatility, monitor Q2 catalysts.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 11, 2026

Across 50 filings in the S&P 500 Consumer Discretionary stream (broadly including retail, services, and adjacent sectors), performance is mixed with robust growth in fintech/services (e.g., OppFi +17% YoY revenue, Wealthfront +18%) contrasting retail weakness (Target -1.7% sales YoY, -2.6% comps). Margin compression is evident in 7/15 quantified firms (avg -150bps, e.g., Oil-Dri -210bps, Target -30bps), driven by higher costs and disruptions, while 5 firms show expansion (e.g., Marvell +770bps to 51%). Major M&A theme emerges with UniFirst/Cintas $5.5B deal (multiple 425s, close H2 2026) and Boxabl/FG Merger advances; capital returns strong via buybacks (Life Time $500M, Wealthfront $100M) and dividends (Smurfit +5%, Oil-Dri +24%). SPAC activity neutral (Pono IPO $150M, LaFayette targets $500M-$1.5B), but biotech/health outliers like Evofem flag going concern risks. Forward catalysts cluster in Apr-May 2026 AGMs; overall, selective opportunities in growth/services amid retail caution.

32 high priority 18 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 11, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (including contextual non-sector filings), healthcare firms exhibit mixed sentiment with biotechs like Minerva Neurosciences, Sagimet Biosciences, and Evofem Biosciences reporting widened net losses (e.g., Minerva -293.4M vs +1.4M prior) but advancing pipelines (Phase 3 initiations Q2 2026), while established players like Johnson & Johnson highlight exceptional 2025 growth in Oncology/Immunology and orthopaedics separation. Period-over-period trends show revenue growth in 12/50 (avg +25% YoY where reported, e.g., Acacia +133%, PNC +7%), but margin compression in 8/50 (avg -150bps, e.g., CID Holdco -3840bps) and net income declines in 10/50 (avg -60%, e.g., Montauk -82%). Capital allocation favors returns (PNC $3.9B dividends/buybacks), with M&A active (Cintas/UniFirst $5.5B EV at 8x EBITDA, accretive). Insider activity limited but neutral (WSFS CEO 10b5-1 sell plan). Key themes: Biotech cash infusions offset losses, cyber risks (Stryker), and AGMs as catalysts; portfolio implication - favor stable healthcare giants over high-burn biotechs amid 2026 trial readouts.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 10, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (with broader sector spillovers), mixed sentiment dominates (24/50 filings), reflecting revenue declines averaging -6% YoY in consumer-facing firms like Kohl's (-4%), Core Molding (-9.5%), and Commercial Vehicle Group (-10.3%), offset by margin expansions (e.g., Kohl's op income +44% Q4 YoY) and operational cash flow improvements (8/15 reporting firms showed +YoY cash flow). Bullish capital allocation trends include $1B TKO buybacks, Stagwell's $350M program expansion, and Oracle's $0.50/share dividend, signaling management conviction amid 7 guidance reaffirmations/raises (e.g., Oracle cloud +46-50% Q4 FY26). Consumer Staples highlights feature Clorox's GOJO acquisition financing, Keurig Dr Pepper's flat coffee sales (+1% FY25) ahead of JDE Peet's spin-off, and ADM board strengthening; however, regulatory risks like Elevance's CMS sanctions (effective Mar 31, 2026) loom. Portfolio-level patterns show 12 firms with >10% YoY revenue growth (tech/cloud leaders like Oracle +22%) vs 18 with declines, with FCF positivity in 9/20 reporting (e.g., Stagwell doubled). M&A activity (5 deals) and equity offerings underscore growth pursuits, but persistent net losses (15 firms) and capex commitments flag cash burn. Actionable now: Prioritize buyback-heavy names and monitor Q1 earnings catalysts for margin inflection.

30 high priority 20 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 10, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (broadly encompassing aerospace, machinery, transportation, construction, with crossovers into related services), proxy season dominates with 15+ DEF/DEFA14A filings highlighting governance enhancements like new Tech Committees (U.S. Bancorp) and board evaluations (Capital City Bank), signaling strong oversight amid April 2026 annual meetings. Financial results show robust revenue growth averaging ~15% YoY where reported (e.g., +49.6% Shoulder Innovations, +29% Opus Genetics, +15.4% Voyager Technologies, +11.3% Barnes & Noble Q3), but widespread profitability pressures with margin compression (ABM -50 bps to 7.1%, Valhi Chemicals swing to -$24.5M loss) and loss widening (Trailblazer -84% assets, Voyager op loss +124%). M&A momentum builds with approvals (Alexander & Baldwin 99% vote, close March 12), financings (Clorox GOJO credit facility, Eaton $8.5B notes for Boyd Thermal), and divestitures (First Guaranty Texas branches). Capital allocation favors returns (ABM $91M buybacks, Enbridge 31st dividend hike +3%, new B&N $0.08 div) amid mixed leverage (ABM 2.9x). Forward catalysts cluster in Q2 (April meetings, B&N Investor Day June 25, LYNX-3 H1), with biotech outliers like Opus PDUFA Oct 2026. Portfolio implication: Favor growth industrials with catalysts over loss-makers; watch margin trends and proxy fights (Sturm Ruger).

22 high priority 28 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 10, 2026

In the S&P 500 Energy stream, Hallador Energy (HNRG) dominates new developments with a positive 8-K announcing a $120M Senior Secured Credit Agreement closed March 5, 2026, refinancing the prior PNC facility, extending maturities to March 5, 2029, and boosting liquidity via a $75M revolver (including $25M LC and $10M swingline) and $45M delayed draw term loan for working capital, growth, and general purposes. CEO Brent Bilsland emphasized improved structure and new lender Texas Capital Bank, signaling strong bank support (9/10 materiality, positive sentiment). ExxonMobil's DEFA14A additional proxy (neutral sentiment, 2/10 materiality) references its Feb 18, 2026 10-K and preliminary proxy with no new financials, metrics, or updates. No period-over-period trends, insider trades, or guidance changes evident across filings, but Hallador's debt extension amid sector volatility highlights balance sheet fortification as a key theme. Portfolio implication: Selective liquidity plays in smaller energy names like HNRG offer alpha vs. mega-caps like XOM showing stasis. Overall, 1/2 filings bullish on capital structure, no margin/revenue trends to aggregate.

1 high priority 1 medium 2 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 10, 2026

Across 50 filings from S&P 500 Financials and adjacent sectors, mixed financial performance prevails with 12/20 quarterly/annual reporters showing revenue growth averaging +14% YoY (e.g., TWFG +22%, Custom Truck +7.9%), but 8/20 facing declines averaging -10% YoY amid volume drops and impairments; margins compressed in 9/15 cases (avg -150 bps) due to cost pressures and start-up expenses. Capital allocation leans defensive with buybacks expanded (News Corp $1B program, Stagwell +$350M to $400M total) and dividends maintained (Kohl's $0.125/share Q1 2026), while equity dilutions via ATMs/private placements hit 7 firms (e.g., Trio $17.4M raised, Aclaris $39.8M). Forward guidance is optimistic in 6/10 cases (e.g., Centene >$3.00 adj EPS, Arq $17-20M EBITDA), offsetting regulatory risks like Elevance CMS sanctions. M&A activity accelerates with approvals (Alexander & Baldwin merger ~Mar 12) and announcements (York Space acquiring Orbion), signaling consolidation. Portfolio-level, financials show yield compression (ACRES -150 bps) but strong balance sheets (M&T 10.84% CET1), with biotech/fintech outliers driving positive catalysts into mid-2026.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 10, 2026

Across the 7 S&P 500 Technology stream filings dated March 10, 2026, key themes include robust cloud and AI-driven growth in established tech leaders like Oracle (+22% YoY total revenue, +44% cloud), contrasted with declines in peripheral holdings like CMCT (-6.3% YoY revenue, net loss widened 53.7%), and progress in quantum tech M&A via dMY Squared's business combination. Period-over-period trends show Oracle as a standout outlier with RPO surging 325% YoY to $553B and raised Q4 FY26 guidance (total revenue +19-21%, cloud +46-50%), while CMCT exhibits segment-wide weakness (office -7.6%, multifamily -19.1%). Proxy filings from IBM (positive sentiment on AI/hybrid cloud) and others signal governance focus and upcoming AGMs, with no insider trading activity reported across filings but capital allocation highlights like Oracle's $0.50 dividend and $30B bond raise. Portfolio-level patterns reveal tech core strength (2/7 filings with strong growth) amid mixed sentiment (3 mixed, 2 positive), implying bullish rotation into cloud/AI plays. Critical developments like dMY's PIPE ($111.9M) and registration effectiveness point to M&A catalysts, while scheduled events create near-term volatility opportunities.

4 high priority 3 medium 7 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 10, 2026

Across the four NASDAQ-100 stream filings dated March 10, 2026, overarching themes include revenue pressures in real estate and coffee segments contrasted by resource expansion and M&A catalysts. CMCT reported 6.3% YoY revenue decline to $116.7M with net loss widening 53.7% to $39.6M due to segment declines and impairments, while KDP Coffee saw flat 1% YoY sales growth to $4.7B, net income down 5% to $700M, but OCF surged 37% to $629M ahead of Q2 2026 spin-off. LBSR aggressively expanded with 13 new claims adding 11.18 sq mi (total footprint +55% to 31.49 sq mi) in Arizona's copper belt, signaling critical minerals upside. Putnam's DEF 14A is routine governance with April 17 AGM. Portfolio trends show mixed sentiment (2/4 mixed, 1 positive, 1 neutral), average materiality 7.5/10, with asset declines at CMCT (-3.4% to $859.2M) vs capex growth at KDP (PPE +9% to $944M). Implications: Avoid overexposed REITs amid margin squeezes, favor mining explorers and M&A plays for alpha amid softening revenues averaging -2.6% YoY where declining.

3 high priority 1 medium 4 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 10, 2026

Across 50 SEC filings from March 10, 2026, primarily non-DJ30 but blue-chip adjacent names show mixed performance with robust revenue growth in defense/security (e.g., Cadre +7.6% YoY sales, AeroVironment +143% Q3) and education retail (Barnes & Noble +11.3% Q3), offset by declines in retail (Kohl's -4% FY), chemicals (Valhi FY loss $57.6M vs profit), and biotechs (Artiva loss +28% YoY). Period-over-period trends reveal 12/20 earnings reporters with YoY revenue growth averaging +25% (outliers Aero +143%, Evolv +40%), but margin compression in 8/15 (avg -100bps, e.g., Aero 38% to 24%) and net losses widening in 10/20 (avg +50%). M&A activity surges with 5 approvals/deals (Alexander & Baldwin 99% vote, York Space shares issued), while banks emphasize governance (M&T CET1 10.84%, US Bancorp new Tech Committee). Forward guidance optimistic in growth names (Cadre +22% 2026 sales), but risks from regulatory (Elevance CMS sanctions Mar 31) and distress (Nine Energy bankruptcy confirmed). Capital allocation favors dividends (Cadre +5.3%, Kohl's $0.125) over buybacks; proxy season ramps with 10+ AGMs in April. Portfolio implication: overweight defense/M&A plays, underweight cyclicals amid mixed sentiment (22 mixed, 10 positive).

19 high priority 31 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 10, 2026

Across 44 SEC filings from the S&P 500 Consumer Discretionary stream (broadly including retail, distribution, leisure, and adjacent financials), mixed sentiment prevails with 70% of financial reporters showing 'mixed' ratings, reflecting revenue growth in high-performers (avg +25% YoY in WLFC 28%, Westrock 40%, TWFG 22%) offset by sales declines in distributors (UNFI -2.6% YoY Q2/Q3). Margin trends diverge: EBITDA expansions (UNFI +23% Q2, WLFC Adj EBITDA +17%) amid op ex cuts, but gross margin compressions (Westrock -560bps to 12.7%, Ultralife impairments) signal scaling costs. Critical developments include M&A (York-Orbion merger, Ashford $95M hotel sale/debt paydown, Infinity Antero acquisition), exec changes (Xponential/SolarEdge CFO departures, Prudential CEO-to-Chairman), and resilient guidance (UNFI raises FY26 EBITDA to $680-710M despite sales cut; Westrock 2026 EBITDA $90-100M +29-44%). Portfolio-level patterns show capital allocation prioritizing debt reduction (Ashford -2.6% indebtedness, UNFI net leverage to 2.3x) and shareholder returns (Enbridge 3% div hike, 31st year; CCEP share repurchases). Consumer spending softness in retail/food distribution contrasts leasing/production strength, implying selective opportunities in growth niches amid macro caution.

26 high priority 18 medium 44 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 10, 2026

Across 33 filings in the USA S&P 500 Healthcare intelligence stream (with extraneous cross-sector inclusions), healthcare firms show mixed performance: managed care leaders like Elevance Health and Centene reaffirmed FY2026 EPS guidance ($25.50+ and >$3.00 adj) despite regulatory headwinds, while biotechs like Lipocine (-82% YoY revenue to $2.0M), Medicinova (+8.6% net loss to $12.0M), and Skye Bioscience (+110% net loss to $55.9M) highlight R&D burn and pipeline risks. Period-over-period trends reveal revenue declines averaging -25% YoY in reporting biotechs/pharma (e.g., Lipocine -82%, CVG proxy -10.3% but non-health), offset by positive trial data (Citius 24% ORR) and leadership stability. No widespread insider trading activity noted, but capital allocation leans defensive with Centene's $1B note redemption and News Corp/Coke buybacks (non-core). Forward-looking catalysts cluster in Q2 2026 (Lipocine NDA, Skye Phase 2b). Portfolio-level: 7/12 core healthcare filings mixed sentiment, margin compression in ops-heavy (e.g., ACRES NII -19% YoY), signaling caution amid regulatory (CMS sanctions March 31) and clinical risks, but opportunities in undervalued pipelines.

19 high priority 14 medium 33 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 09, 2026

Across the 50 filings in the USA S&P 500 Consumer Staples intelligence stream (though spanning diverse sectors including logistics, biotech, SPACs, and select staples-adjacent like Kronos TiO2 for coatings/paper), sentiment is predominantly mixed (12/50), with revenue growth in 7/12 reporting companies averaging +24% YoY (e.g., FuelCell +61%, Myomo +26%, Amex GBT +12% FY) offset by widespread margin compression averaging -143 bps (e.g., Amex GBT -243 bps Q4, Myomo -550 bps FY) and impairments/losses (Kronos FY loss swing, ULH $124M impairment). Period-over-period trends reveal top-line resilience in services/biotech amid cost pressures, with 5/8 companies showing gross margin declines despite volume/AUR gains (Signet SSS +1.2% FY but promotions hit margins). Capital allocation leans shareholder-friendly with $100M+ buybacks (Kimbell, Amex GBT doubled to $600M) and steady dividends (Ellington $0.08/share), while financings exceed $500M (Korro $85M PIPE, OPAL $180M). Insider activity is sparse but stable (lululemon activist holds 8.4%), no major sells flagged. Forward-looking catalysts cluster in Q1-Q2 2026 (Myomo rev guidance $43-46M, annual meetings April, Relmada Phase 3 mid-2026), signaling near-term volatility but growth potential in resilient segments. Portfolio implication: Favor cos with strong guidance/backlogs (Korn Ferry +11% remaining fees) over impairment-heavy names (ULH, Kronos).

25 high priority 25 medium 50 total filings